Arvinas to Present New Phase 3 and Phase 2 Vepdegestrant Clinical Trial Data at 2025 ESMO Congress
Arvinas Inc. will present new data from its vepdegestrant clinical trials at the 2025 ESMO Congress in Berlin, scheduled for October 17-21, 2025. The investigational drug, developed with Pfizer, targets ER+/HER2- advanced breast cancer. Presentations will include patient-reported outcomes from the Phase 3 VERITAC-2 trial and results from the Phase 2 TACTIVE-N study. This information has not been previously disclosed and will be shared at the congress.
Arvinas Inc. announced that new data from its vepdegestrant clinical development program will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress, scheduled for October 17-21, 2025, in Berlin, Germany. Vepdegestrant, an investigational PROTAC estrogen receptor degrader developed in partnership with Pfizer Inc., is being studied as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations in the second line-plus setting, as well as in combination therapies for ER+/HER2- breast cancer. The presentations will include new patient-reported outcomes data from the Phase 3 VERITAC-2 trial and results from the Phase 2 TACTIVE-N study in postmenopausal patients with localized ER+/HER2- breast cancer. The results have not yet been presented and will be shared during the ESMO Congress. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543376-en) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
